BusinessPeregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of BavituximabBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy ConferencesBy Nasdaq OMXJan 20, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 7, 2015, 9:05 PM UTC
